Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial

Table 1 Demographic and baseline characteristics of the study population in the two groups, n (%)

	Placebo group	rhBNP group	P value
Age (mean ± SD)	75.42 ± 12.88	75.58 ± 12.69	0.943
Male	49 (74.2)	43 (66.2)	0.311
Hypertension	36 (54.5)	32 (49.2)	0.543
Diabetes	7 (10.6)	8 (12.3)	0.760
Hyperlipemia	46 (69.7)	43 (66.2)	0.664
Smoking	18 (27.3)	15 (23.1)	0.580
Killip score (mean ± SD)	2.15 ± 0.52	2.09 ± 0.49	0.498
B natriuretic peptide [median (Q1, Q3)]	69 (18384)	78 (35621)	0.752
Troponin I (ng/L, mean ± SD)	55.18 ± 10.22	53.29 ± 11.08	0.312
Treatment			0.635
Coronary arteriography	9 (13.6)	11 (16.9)	0.759
PCI	57 (86.4)	54 (83.1)	0.787
Lesion location
Left main	7 (10.6)	5 (7.7)	0.563
Left anterior descending branch	30 (45.5)	34 (52.3)	0.433
Left circumflex branch	12 (18.2)	9 (13.8)	0.499
Right coronary artery	17 (25.7)	17 (26.2)	0.959
LVEF (%, mean ± SD)	59.47 ± 3.29	60.16 ± 3.15	0.223
Contrast agent dosage [mL, median (Q1, Q3)]	135 (60175)	130 (70160)	0.912
Intro-operative IABP	7 (10.6)	8 (12.3)	0.760
Hospitalized
ACEI/ARB	35 (53.0)	32 (48.5)	0.664
Receptor antagonist	52 (78.8)	56 (86.2)	0.268
Calcium channel blocker	29 (43.9)	27 (41.5)	0.781
Natriuretic agent	22 (33.3)	25 (38.5)	0.541

rhBNP: Recombinant human brain natriuretic peptide; PCI: Percutaneous coronary intervention.

Table 2 Renal indexes after primary percutaneous coronary intervention in the two groups

	Placebo	rhBNP	P value
Serum creatinine (mol/L)
Preoperative	72.35 ± 15.38	74.13 ± 16.28	0.521
24 h	85.74 ± 19.21	83.26 ± 18.12	0.449
48 h	101.55 ± 21.22	80.59 ± 19.46	0.001
72 h	88.15 ± 18.72	76.29 ± 16.55	0.007
Cystatin C (mg/L)
Preoperative	0.91 ± 0.22	0.93 ± 0.21	0.596
24 h	0.95 ± 0.25	0.96 ± 0.31	0.839
48 h	1.07 ± 0.37	0.93 ± 0.32	0.020
72 h	1.02 ± 0.30	0.88 ± 0.25	0.004
Creatinine clearance rate (mL/min)
Preoperative	1.12 ± 0.31	1.15 ± 0.38	0.621
24 h	0.95 ± 0.32	1.03 ± 0.34	0.168
48 h	0.82 ± 0.29	0.95 ± 0.28	0.010
72 h	0.86 ± 0.25	1.05 ± 0.37	0.001
eGFR [mL/(min/1.73 m2)]
Preoperative	85.76 ± 22.46	86.35 ± 21.27	0.877
24 h	78.43 ± 9.12	82.11 ± 10.23	0.030
48 h	76.82 ± 8.55	83.27 ± 10.13	0.001
72 h	77.432 ± 5.120	85.38 ± 7.22	0.001

rhBNP: Recombinant human brain natriuretic peptide.

Table 3 Clinical outcomes and complications in the two groups, n (%)

	Placebo	rhBNP	P value
Cardiogenic death	6 (9.1)	5 (7.7)	0.773
Recurrent myocardial infarction	3 (4.5)	3 (1.5)	1.000
Acute heart failure	15 (22.7)	5 (7.7)	0.017
CIN	14 (21.2)	5 (9.2)	0.028

CIN: Contrast-induced nephropathy; rhBNP: Recombinant human brain natriuretic peptide.